PepVault
/ database / GLP-1 / GIP Dual Agonist

Tirzepatide

Also: Mounjaro · Zepbound

Dual-agonist successor to semaglutide — larger average weight loss in trials.

Evidence
established
Legal status
rx only
Half-life
~5 days
Routes
subq
View on Limitless LifeAdd to compare
What it is

Tirzepatide acts on both GLP-1 and GIP receptors, producing greater average weight loss than semaglutide in head-to-head studies. It is approved for type 2 diabetes and chronic weight management.

Mechanism

Dual GLP-1 + GIP receptor agonist. Produces deeper appetite suppression and metabolic improvements than GLP-1 alone.

Outcomes it's matched to
Safety

GI side effects common. Same MTC warning as semaglutide.

  • MTC history
  • MEN-2
  • Pregnancy
Legal context

Prescription medication.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault